MissionIR would like to highlight CytRx Corp. (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology. The company’s pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib.
In the company’s news,
Seeking Alpha yesterday published the following article featuring CytRx: http://seekingalpha.com/article/1700372-cytrx-corporation-remains-an-undiscovered-opportunity-inthe-cancer-space?source=yahoo#comments_header
Released On: 4/8/2016
Views: 3837
Released On: 4/7/2016
Views: 4574
Released On: 3/31/2016
Views: 3547
Released On: 3/24/2016
Views: 2904
Released On: 3/17/2016
Views: 2462
Released On: 3/11/2016
Views: 2288
Released On: 3/4/2016
Views: 2603
Released On: 3/3/2016
Views: 2300
Released On: 2/23/2016
Views: 3653
Released On: 2/12/2016
Views: 2648
Released On: 2/10/2016
Views: 2355
Released On: 2/9/2016
Views: 2515
Released On: 1/20/2016
Views: 4294
Released On: 1/14/2016
Views: 4757
Released On: 1/5/2016
Views: 3003
Released On: 12/18/2015
Views: 9317
Released On: 12/9/2015
Views: 2764
Released On: 12/3/2015
Views: 3197